3-Bromo-benzoyl isocyanate | 4461-35-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Bromo-benzoyl isocyanate
• 英文别名: 3-Bromobenzoyl isocyanate；3-bromobenzoyl isocyanate
• CAS: 4461-35-2
• 化学式: C₈H₄BrNO₂
• 分子量: 226.029
• InChiKey: HQIZURFZFZULEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,2,3,4-四氢喹啉 、 3-Bromo-benzoyl isocyanate 以 甲苯 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  N-取代的苯甲酰基-1,2,3,4-四氢喹啉基-1-羧酰胺的设计，合成及杀真菌活性

  摘要：

  为了寻找具有高生物活性的新的铅化合物，采用连接活性亚结构法设计了一系列N-取代的苯甲酰基-1,2,3,4-四氢喹啉基-1-羧酰胺。由取代的苯甲酸按四个步骤合成目标化合物，并通过1 H NMR，IR光谱和元素分析确定其结构。体外生物测定结果表明，某些目标化合物表现出优异的杀真菌活性，且取代基的位置在杀真菌活性中起重要作用。特别是，化合物5n对两种测试真菌Valsa mali和Sclerotionia sclerotiorum的杀真菌活性比市售杀真菌剂氟苯尼更好。，其EC 50值分别为3.44和2.63 mg / L。而且它还显示出良好的针对核盘菌的体内杀真菌活性，其EC 50值为29.52 mg / L。

  DOI：

  10.1016/j.bmcl.2016.03.085
• 作为产物：
  描述：

  间溴苯甲酸 在 ammonium hydroxide 、 氯化亚砜 作用下， 以 1,2-二氯乙烷 、 甲苯 为溶剂， 反应 10.0h， 生成 3-Bromo-benzoyl isocyanate
  参考文献：
  名称：

  N-取代的苯甲酰基-1,2,3,4-四氢喹啉基-1-羧酰胺的设计，合成及杀真菌活性

  摘要：

  为了寻找具有高生物活性的新的铅化合物，采用连接活性亚结构法设计了一系列N-取代的苯甲酰基-1,2,3,4-四氢喹啉基-1-羧酰胺。由取代的苯甲酸按四个步骤合成目标化合物，并通过1 H NMR，IR光谱和元素分析确定其结构。体外生物测定结果表明，某些目标化合物表现出优异的杀真菌活性，且取代基的位置在杀真菌活性中起重要作用。特别是，化合物5n对两种测试真菌Valsa mali和Sclerotionia sclerotiorum的杀真菌活性比市售杀真菌剂氟苯尼更好。，其EC 50值分别为3.44和2.63 mg / L。而且它还显示出良好的针对核盘菌的体内杀真菌活性，其EC 50值为29.52 mg / L。

  DOI：

  10.1016/j.bmcl.2016.03.085

文献信息

• Discovery of Cytochrome P450 4F11 Activated Inhibitors of Stearoyl Coenzyme A Desaturase
  作者：Sarah E. Winterton、Emanuela Capota、Xiaoyu Wang、Hong Chen、Prema L. Mallipeddi、Noelle S. Williams、Bruce A. Posner、Deepak Nijhawan、Joseph M. Ready

  DOI：10.1021/acs.jmedchem.8b00052

  日期：2018.6.28

  Stearoyl-CoA desaturase (SCD) catalyzes the first step in the conversion of saturated fatty acids to unsaturated fatty acids. Unsaturated fatty acids are required for membrane integrity and for cell proliferation. For these reasons, inhibitors of SCD represent potential treatments for cancer. However, systemically active SCD inhibitors result in skin toxicity, which presents an obstacle to their development

  硬脂酰辅酶A去饱和酶（SCD）催化饱和脂肪酸向不饱和脂肪酸转化的第一步。膜完整性和细胞增殖需要不饱和脂肪酸。由于这些原因，SCD抑制剂代表了潜在的癌症治疗方法。但是，具有内在活性的SCD抑制剂会导致皮肤毒性，这对它们的发展构成了障碍。我们最近描述了一系列草酸二酰胺，它们通过CYP4F11介导的代谢转化为癌症子集内的活性SCD抑制剂。在本文中，我们描述了草酸二酰胺和相关N-酰基脲的优化，以及与代谢活化和SCD抑制有关的结构-活性关系的分析。
• Scalable Synthetic Strategy for Unsymmetrical Trisubstituted <i>s</i>-Triazines
  作者：Helong Liang、Ganzhong Li、Lei Zhang、Gefei Wang、Mingyu Song、Heng Li、Bingxin Yuan

  DOI：10.1021/acs.orglett.1c01970

  日期：2021.8.6

  variety of unsymmetrical trisubstituted 1,3,5-triazines was developed. This protocol applied in situ formed acyl isocyanate from amide to react with amidine, introducing two substituents to the 1,3,5-triazinone ring with a low production cost and a simple workup procedure. The scalability of this method was demonstrated by translating a small-scale procedure to a multi-kilogram-scale synthesis. Chlorination

  开发了一种可扩展的合成策略来生产多种不对称的三取代 1,3,5-三嗪。该方案应用由酰胺原位形成的酰基异氰酸酯与脒反应，以较低的生产成本和简单的后处理程序将两个取代基引入 1,3,5-三嗪酮环。该方法的可扩展性通过将小规模程序转化为数公斤规模的合成来证明。氯化和与各种亲核试剂的进一步偶联反应可以提供带有不同官能团的不对称三取代 1,3,5-三嗪。
• 10.1016/j.tet.2024.134009
  作者：Zhao, Jing、Chen, Yuanyuan、Wang, Xingyi、Yang, Weiqing、Zhang, Aigui、Qu, Zhonghua、Fu, Haiyan、Ma, Menglin

  DOI：10.1016/j.tet.2024.134009

  日期：——

  chloride. Subsequently, 21 target products of 2-chloro-4-R-6-R-1,3,5-triazines compounds were obtained through the cyclization of substituted benzoyl isocyanates with benzamidine hydrochloride at relatively low temperatures and a one-pot chlorination reaction. The second method involved the synthesis of the same 21 compounds of 2-chloro-4-R-6-R-1,3,5-triazines by reacting benzamide with oxalyl chloride

  据报道，一种合成具有三个不同取代基的 1,3,5-三嗪的新方法。关键中间体2-氯-4-R-6-R-1,3,5-三嗪的合成对于获得具有三个不同取代基的1,3,5-三嗪起着关键作用。本文介绍了两种创新的一锅法合成各种取代的 2-氯-4-R-6-R-1,3,5-三嗪。在第一种方法中，首先通过不同的酰胺与草酰氯反应合成取代的苯甲酰基异氰酸酯。随后，通过取代苯甲酰基异氰酸酯与盐酸苯甲脒在较低温度下环合，一锅法氯化反应，得到21种目标产物2-氯-4-R-6-R-1,3,5-三嗪类化合物。第二种方法是通过苯甲酰胺与草酰氯反应，然后与不同的盐酸脒环合，然后一锅法合成相同的21种2-氯-4-R-6-R-1,3,5-三嗪化合物。氯化反应。最终，通过各种反应成功合成了总共35种不同的不对称三取代1,3,5-三嗪化合物。
• Naito; Nakagawa; Okumura, Journal of Antibiotics, 1965, vol. 18, # 4, p. 145 - 157
  作者：Naito、Nakagawa、Okumura、Konishi、Kawaguchi

  DOI：——

  日期：——
• Novel acyl carbamates and acyl / diacyl ureas show in vitro efficacy against Toxoplasma gondii and Cryptosporidium parvum
  作者：Kun Li、Gregory M. Grooms、Shahbaz M. Khan、Anolan Garcia Hernandez、William H. Witola、Jozef Stec

  DOI：10.1016/j.ijpddr.2020.08.006

  日期：2020.12

  Toxoplasma gondii and Cryptosporidium parvum are protozoan parasites that are highly prevalent and opportunistically infect humans worldwide, but for which completely effective and safe medications are lacking. Herein, we synthesized a series of novel small molecules bearing the diacyl urea scaffold and related structures, and screened them for in vitro cytotoxicity and antiparasitic activity against T. gondii and C. parvum. We identified one compound (GMG-1-09), and four compounds (JS-1-09, JS-2-20, JS-2-35 and JS-2-49) with efficacy against C. parvum and T. gondii, respectively, at low micromolar concentrations and showed appreciable selectivity in human host cells. Among the four compounds with efficacy against T. gondii, JS-1-09 representing the diacyl urea scaffold was the most effective, with an anti-Toxoplasma IC₅₀ concentration (1.21 μM) that was nearly 53-fold lower than its cytotoxicity IC₅₀ concentration, indicating that this compound has a good selectivity index. The other three compounds (JS-2-20, JS-2-35 and JS-2-49) were structurally more divergent from JS-1-09 as they represent the acyl urea and acyl carbamate scaffold. This appeared to correlate with their anti-Toxoplasma activity, suggesting that these compounds' potency can likely be enhanced by selective structural modifications. One compound, GMG-1-09 representing acyl carbamate scaffold, depicted in vitro efficacy against C. parvum with an IC₅₀ concentration (32.24 μM) that was 14-fold lower than its cytotoxicity IC₅₀ concentration in a human intestinal cell line. Together, our studies unveil a series of novel synthetic acyl/diacyl urea and acyl carbamate scaffold-based small molecule compounds with micromolar activity against T. gondii and C. parvum that can be explored further for the development of the much-needed novel anti-protozoal drugs.